Arian Frasheri - Concepedia

Author

Arian Frasheri

Maria Eleonora Hospital

Also Known As

A Frasheri, A. Frasheri, Arian Frasheri, Frasheri, A

Publications

957

Citations

H-Index

Concepts

All Affiliations

Maria Eleonora Hospital University of Palermo Hospital Universitario Puerta de Hierro Majadahonda Ospedale San Giovanni Bosco Azienda Ospedale - Università Padova

About

Arian Frasheri is an author at Maria Eleonora Hospital specializing in cardiovascular disease, atherosclerosis, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	768
2	Public Health	4	4	121
3	Epidemiology	4	4	121
4	Diabetes	3	3	55
5	Biochemistry	1	1	19

Arian Frasheri

Publications

896

Citations

H-Index

Page 1

	Year	Citations
Second-Generation Drug-Eluting Stent Implantation Followed by 6- Versus 12-Month Dual Antiplatelet Therapy Antonio Colombo, Alaide Chieffo, Arian Frasheri, Journal of the American College of Cardiology ThrombosisEndovascular TechniqueCardiovascular DiseaseBlood PlateletVascular Surgery	2014	414
Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis Remo Albiero, Sigmund Silber, Carlo Di Mario, Journal of the American College of Cardiology Conventional Balloon AngioplastyEndovascular TechniqueCardiovascular DiseaseIn-stent RestenosisVascular Surgery	2004	208
Small, dense low‐density lipoproteins (LDL) are predictors of cardio‐ and cerebro‐vascular events in subjects with the metabolic syndrome Manfredi Rizzo, Vincenzo Pernice, Arian Frasheri, Clinical Endocrinology	2008	111
Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease Manfredi Rizzo, Vincenzo Pernice, Arian Frasheri, Atherosclerosis Metabolic SyndromeCardiovascular DiseaseLdl SizeAtherogenic Lipoprotein PhenotypePeripheral Artery Disease	2007	77
Optimal duration of dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes: The SECURITY (Second-Generation Drug-Eluting Stent Implantation Followed By Six- Versus Twelve-Month Dual Antiplatelet Therapy)-diabetes substudy Giuseppe Tarantini, Luca Nai Fovino, Paola Tellaroli, International Journal of Cardiology ThrombosisDiabetes ManagementDual Antiplatelet TherapyOptimal DurationCardiovascular Disease	2016	25
Accumulation of apoE-enriched triglyceride-rich lipoproteins in patients with coronary artery disease Carlo M. Barbagallo, Manfredi Rizzo, Davide Noto, Metabolism Metabolic SyndromeBiochemistryCardiovascular DiseaseApoe-enriched Triglyceride-rich LipoproteinsMedicine	2006	19
Association between Tpeak-Tend/QT and major adverse cardiovascular events in patients with Takotsubo syndrome Annabella Braschi, Arian Frasheri, Renzo M Lombardo, Acta cardiologica. Supplementum	2020	17
Small, dense low-density lipoproteins are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome. Manfredi Rizzo, Vincenzo Pernice, Arian Frasheri, Nova Science Publishers (Nova Science Publishers, Inc.) ObesityMetabolic SyndromeCerebro-vascular EventsCardiovascular EpidemiologyCardiovascular Disease	2008	14
Family history, diabetes and extension of coronary atherosclerosis are strong predictors of adverse events after PTCA: A one-year follow-up study Manfredi Rizzo, Carlo M. Barbagallo, Davide Noto, Nutrition Metabolism and Cardiovascular Diseases One-year Follow-up StudyFamily MedicineAdverse EventsCoronary AtherosclerosisDiabetes Epidemiology	2005	11

Page 1